Nanotax Clinical Trial

Kansas Cancer Treatment

Intraperitoneal Chemotherapy for Ovarian Cancer

as well as other peritoneal cancers

Nanotax® Phase I Trial in Peritoneal Cancers

(National Cancer Institute description)

Nanotax is currently enrolling patients in a Phase 1 Clinical Trial for peritoneal cancers including: ovarian, mullerian tumors, gastrointestinal or metastatic tumors to the peritoneum. This trial will enroll approximately 24 patients who have failed all other therapies available. The study involves surgical placement of a peritoneal port allowing for direct delivery of Nanotax to the peritoneal cavity. The study is currently open at The University of Kansas Cancer Center located in Westwood, Kansas.

Paclitaxel is a commonly used chemotherapy drug that is known to have serious side effects. The side effects are due in large part to the solvent that Paclitaxel must be mixed with in order to be given to a patient. Nanotax is a reformulation of Paclitaxel that allows it to be mixed with water and then administered to patients.

Criterion For Participation

Patients must have carcinoma predominantly confined to the peritoneal cavity.
Patients must have failed all other standard therapies.
At least 28 days must have passed since completion of the previous chemotherapy treatment.
Patients must have a pretreatment granulocyte count of = 1,500/µL and platelet count = 100,000/µL.
There are additional requirements outlined in the Protocol on the National Cancer Institute website.

Intraperitoneal Chemotherapy for Cancers of the Peritoneum

Approximately 22,000 women are diagnosed with ovarian cancer in the United States every year. Often times, it is detected after it has metastized because the symptoms are hard to detect. For most cancers, there are three standard treatment options, including: surgery, radiation treatment and chemotherapy.

Nanotax utilizes a new delivery method for peritoneum cancers. Chemotherapy is delivered directly into the area in which the cancer is located, as opposed to injection into the blood stream.

Nanotax was developed in collaboration with the following:

CritiTech, Inc.

The University of Kansas Cancer Center

More Information

If you are interested in learning more about this trial or other cancer clinical trials, contact The University of Kansas Cancer Center at: 913-588-4700 or visit http://cancer.kumc.edu.